Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

CyPass Clinical Experience Study (CyCLE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Transcend Medical, Inc.
ClinicalTrials.gov Identifier:
NCT01097174
First received: March 30, 2010
Last updated: October 3, 2016
Last verified: October 2016
  Purpose
This study is to evaluate the long-term safety, effectiveness and clinical experience of the CyPass Micro-Stent in patients with glaucoma.

Condition Intervention
Open Angle Glaucoma (OAG)
Device: CyPass Micro-Stent

Study Type: Observational
Study Design: Observational Model: Case-Only
Official Title: A Multicenter Registry Study to Capture Data With Respect to CyPass Clinical Experience

Resource links provided by NLM:


Further study details as provided by Transcend Medical, Inc.:

Primary Outcome Measures:
  • Incidence of intraoperative and postoperative adverse events [ Time Frame: Day 0 - Year 3 ]

Secondary Outcome Measures:
  • Intraocular pressure (IOP) reduction [ Time Frame: 1 - 36 months postoperatively ]
  • Ocular hypotensive medication use [ Time Frame: 1 - 36 months postoperatively ]

Enrollment: 555
Study Start Date: December 2009
Study Completion Date: July 2015
Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
CyPass Micro-stent
Patients in whom CyPass Micro-stent implantation was attempted.
Device: CyPass Micro-Stent
The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of they eye.

  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Glaucoma
Criteria

Inclusion Criteria:

  • Diagnosis of OAG
  • IOP ≥ 21 mmHg and ≤ 31 mmHg (with or without ocular hypotensive medication)

Exclusion Criteria:

  • Acute angle closure, narrow angle, uveitic or neovascular glaucoma
  • Normal tension glaucoma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01097174

Locations
Austria
University Eye Clinic
Salzburg, Austria
Bulgaria
Specialized Hospital for Active Treatment of Ophthalmologic Diseases
Sofia, Bulgaria
Germany
Schlosspark-Klinik, Department of Ophthalmology
Berlin, Germany
Knappschaftskrankenhaus Bochum-Langendreer
Bochum, Germany
AugenKlinik Cham
Cham, Germany
Klinik fur Augenheilkunde, Campus Lubeck
Lubeck, Germany
Klinik für Augenheilkunde, Dietrich-Bonhoeffer-Klinikum
Neubrandenburg, Germany
Italy
Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazio
Catania, Italy
Poland
Wojskowy Instytut Medyczny (Military Medical Institute)
Warsaw, Poland
Spain
Institut Catala de Retina
Barcelona, Spain
Instituto de Microcirugia Ocular
Barcelona, Spain
Hospital Clinico San Carlos
Madrid, Spain
Ramón y Cajal University Hospital
Madrid, Spain
Hospital Universiatrio Miguel Servet
Zaragoza, Spain
Sponsors and Collaborators
Transcend Medical, Inc.
Investigators
Study Director: Tsontcho (Sean) Ianchulev, MD, MPH Transcend Medical, Inc.
  More Information

Responsible Party: Transcend Medical, Inc.
ClinicalTrials.gov Identifier: NCT01097174     History of Changes
Other Study ID Numbers: TMI-09-02
Study First Received: March 30, 2010
Last Updated: October 3, 2016

Keywords provided by Transcend Medical, Inc.:
Glaucoma
Glaucoma device
Glaucoma surgery
Intraocular pressure

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases

ClinicalTrials.gov processed this record on April 26, 2017